Pattern of planned systemic therapy usage in newly diagnosed, nonmetastatic squamous cell carcinoma of the head and neck in a commercially insured population in the United States

Jong Chul Park, Christine Gourin, Ana Ponce Kiess, Ranee Mehra, Arlene A. Forastiere, Hyunseok Kang

Research output: Contribution to journalArticle

Abstract

Background: We analyzed systemic therapy plans submitted for commercially insured patients with untreated, newly diagnosed squamous cell carcinoma of the head and neck (SCCHN) to investigate patterns of practice. Methods: Consecutive chemotherapy treatment plans were submitted using Eviti Connect (https://www.marylandphysicianscare.com/content/dam/centene/maryland/pdfs/evitiConnectFactSheet.pdf) portal for preauthorization between June 1, 2011, and June 30, 2015, were analyzed. Results: A total of 387 treatment plans were submitted for 340 patients; 68 and 272 patients were from academic centers and community practices, respectively. Single agent cisplatin (57%), cetuximab (18%), and carboplatin (9%) were the most commonly proposed regimens concurrent with definitive radiotherapy (RT). The frequency of cetuximab use was not significantly different between academic centers and community practices. A clinical trial was proposed in only 15% of patients. Conclusion: Among commercially insured patients with newly diagnosed, nonmetastatic SCCHN, the choice of systemic therapy in initial treatment plans was not significantly different between academic centers and community practices. Clinical trials are underutilized and should be encouraged.

Original languageEnglish (US)
JournalHead and Neck
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Population
Clinical Trials
Therapeutics
Carboplatin
Cisplatin
Radiotherapy
Carcinoma, squamous cell of head and neck
Drug Therapy
Cetuximab

Keywords

  • commercially insured
  • concurrent therapy
  • initial treatment strategy
  • pattern of practice
  • squamous cell carcinoma of the head and neck

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

@article{1a67d25bff1e4822807505e07426d9ad,
title = "Pattern of planned systemic therapy usage in newly diagnosed, nonmetastatic squamous cell carcinoma of the head and neck in a commercially insured population in the United States",
abstract = "Background: We analyzed systemic therapy plans submitted for commercially insured patients with untreated, newly diagnosed squamous cell carcinoma of the head and neck (SCCHN) to investigate patterns of practice. Methods: Consecutive chemotherapy treatment plans were submitted using Eviti Connect (https://www.marylandphysicianscare.com/content/dam/centene/maryland/pdfs/evitiConnectFactSheet.pdf) portal for preauthorization between June 1, 2011, and June 30, 2015, were analyzed. Results: A total of 387 treatment plans were submitted for 340 patients; 68 and 272 patients were from academic centers and community practices, respectively. Single agent cisplatin (57{\%}), cetuximab (18{\%}), and carboplatin (9{\%}) were the most commonly proposed regimens concurrent with definitive radiotherapy (RT). The frequency of cetuximab use was not significantly different between academic centers and community practices. A clinical trial was proposed in only 15{\%} of patients. Conclusion: Among commercially insured patients with newly diagnosed, nonmetastatic SCCHN, the choice of systemic therapy in initial treatment plans was not significantly different between academic centers and community practices. Clinical trials are underutilized and should be encouraged.",
keywords = "commercially insured, concurrent therapy, initial treatment strategy, pattern of practice, squamous cell carcinoma of the head and neck",
author = "Park, {Jong Chul} and Christine Gourin and Kiess, {Ana Ponce} and Ranee Mehra and Forastiere, {Arlene A.} and Hyunseok Kang",
year = "2018",
month = "1",
day = "1",
doi = "10.1002/hed.25333",
language = "English (US)",
journal = "Head and Neck Surgery",
issn = "0148-6403",
publisher = "Wiley-Liss Inc.",

}

TY - JOUR

T1 - Pattern of planned systemic therapy usage in newly diagnosed, nonmetastatic squamous cell carcinoma of the head and neck in a commercially insured population in the United States

AU - Park, Jong Chul

AU - Gourin, Christine

AU - Kiess, Ana Ponce

AU - Mehra, Ranee

AU - Forastiere, Arlene A.

AU - Kang, Hyunseok

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: We analyzed systemic therapy plans submitted for commercially insured patients with untreated, newly diagnosed squamous cell carcinoma of the head and neck (SCCHN) to investigate patterns of practice. Methods: Consecutive chemotherapy treatment plans were submitted using Eviti Connect (https://www.marylandphysicianscare.com/content/dam/centene/maryland/pdfs/evitiConnectFactSheet.pdf) portal for preauthorization between June 1, 2011, and June 30, 2015, were analyzed. Results: A total of 387 treatment plans were submitted for 340 patients; 68 and 272 patients were from academic centers and community practices, respectively. Single agent cisplatin (57%), cetuximab (18%), and carboplatin (9%) were the most commonly proposed regimens concurrent with definitive radiotherapy (RT). The frequency of cetuximab use was not significantly different between academic centers and community practices. A clinical trial was proposed in only 15% of patients. Conclusion: Among commercially insured patients with newly diagnosed, nonmetastatic SCCHN, the choice of systemic therapy in initial treatment plans was not significantly different between academic centers and community practices. Clinical trials are underutilized and should be encouraged.

AB - Background: We analyzed systemic therapy plans submitted for commercially insured patients with untreated, newly diagnosed squamous cell carcinoma of the head and neck (SCCHN) to investigate patterns of practice. Methods: Consecutive chemotherapy treatment plans were submitted using Eviti Connect (https://www.marylandphysicianscare.com/content/dam/centene/maryland/pdfs/evitiConnectFactSheet.pdf) portal for preauthorization between June 1, 2011, and June 30, 2015, were analyzed. Results: A total of 387 treatment plans were submitted for 340 patients; 68 and 272 patients were from academic centers and community practices, respectively. Single agent cisplatin (57%), cetuximab (18%), and carboplatin (9%) were the most commonly proposed regimens concurrent with definitive radiotherapy (RT). The frequency of cetuximab use was not significantly different between academic centers and community practices. A clinical trial was proposed in only 15% of patients. Conclusion: Among commercially insured patients with newly diagnosed, nonmetastatic SCCHN, the choice of systemic therapy in initial treatment plans was not significantly different between academic centers and community practices. Clinical trials are underutilized and should be encouraged.

KW - commercially insured

KW - concurrent therapy

KW - initial treatment strategy

KW - pattern of practice

KW - squamous cell carcinoma of the head and neck

UR - http://www.scopus.com/inward/record.url?scp=85056380537&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056380537&partnerID=8YFLogxK

U2 - 10.1002/hed.25333

DO - 10.1002/hed.25333

M3 - Article

C2 - 30421818

AN - SCOPUS:85056380537

JO - Head and Neck Surgery

JF - Head and Neck Surgery

SN - 0148-6403

ER -